ASH Abstracts Referenced

Early Prophylaxis Provides Continued Joint Protection in Severe Hemophilia a: Results of the Joint Outcome Continuation Study

B-YOND Final Results Confirm Established Safety, Sustained Efficacy, and Extended Dosing Interval for Up to 4 Years of Treatment With rFIXFc in Previously Treated Subjects With Severe Hemophilia B

Real-World Data on the Use of rFIXFc in Subjects With Hemophilia B for Up to 3.7 Years Demonstrates Improved Bleed Control and Adherence With Reduced Treatment Burden

Immunogenicity of Two Plasma-Derived FVIII Products and Simoctocog Alfa in Previously Untreated Patients According to F8 Mutation Type

Emicizumab Prophylaxis Provides Flexible and Effective Bleed Control in Children with Hemophilia A with Inhibitors: Results from the HAVEN 2 Study

The Atlanta Protocol: Immune Tolerance Induction in Pediatric Patients with Hemophilia a and Inhibitors on Emicizumab

Real World Use of Extended Half-Life Products and the Impact on Bleeding Events and Joint Health in the United States

Adoption of Prophylaxis in the United States in the Era of Extended Half-Life Factor Concentrates

Personalization of Treatment Regimens for Active Patients: A Comparison of Hemophilia Prophylaxis Treatment Regimens

A New Dosing Model Based on Body Mass Index to Guide Factor VIII Dosing in Patients with Hemophilia A

References


